Morgan Bayer

Enfortumab vedotin significantly improved outcomes for patients with unresectable or metastatic urothelial carcinoma, according to real-world data.

G-CSF use and docetaxel dose modifications allowed patients with mHSPC to receive efficacious doses of docetaxel in the ARASENS trial.

Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.

Selinexor plus ruxolitinib showed activity in patients with myelofibrosis who were treated with ruxolitinib.

Treatment with navtemadlin lowered the levels of biomarkers of disease burden in patients with relapsed/refractory myelofibrosis.

Advancements in FL treatment, including BTK inhibitors and CAR T-cell therapies, offer new hope for relapsed or refractory cases.

Tremelimumab plus durvalumab sustained an overall survival improvement in unresectable hepatocellular carcinoma.

Laurence Albiges, MD, PhD, discusses research evaluating treatments for subtypes of non–clear cell renal cell carcinoma.

Nivolumab plus ipilimumab and chemotherapy elicited a durable, long-term survival benefit vs chemotherapy alone in metastatic NSCLC.

Cilta-cel continues to elicit deep and durable responses in patients with early relapsed multiple myeloma, including those refractory to lenalidomide.

Ruxolitinib and belumosudil demonstrated a beneficial ORR, indicating synergistic effects in targeting multiple inflammatory pathways in chronic GVHD.

Real-world recurrence and prognosis was determined through the identification of morphologic RCC types and tumor stages.

Fostroxacitabine bralpamide plus lenvatinib displayed preliminary efficacy with a tolerable safety profile in patients with hepatocellular carcinoma.

The phase 1a/1b NX-1607-101 trial will evaluate NX-1607, a CBL-B inhibitor, in patients with advanced malignancies, including diffuse large B-cell lymphoma.

The phase 2 BBI-20231001 trial evaluating the Boltbody immune-stimulating antibody conjugate BDC-1001 with or without pertuzumab in patients with HER2-positive breast adenocarcinoma is open for enrollment in the United States, France, Italy, and Spain.

Bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride generated robust responses with a tolerable safety profile when delivered as first-line therapy in patients with marginal zone lymphoma.

Patients with chronic lymphoctyic leukemia treated with pirtobrutinib monotherapy experienced comparable objective response rates regardless of acquired BTK mutation and a decrease or clearance of BTK cysteine 481 clones despite the emergence of non-C481 clones or other less common mutations during or near the time of progression.

Exercises such as resistance training and walking were safe and effective interventions that were associated with improved frailty scores in patients with multiple myeloma receiving systemic treatment.

Treatment with durvalumab was associated with lower real-world progression-free survival in patients with unresectable, stage III EGFR-mutated non–small cell lung cancer vs patients with EGFR wild-type disease.